By Eric Sagonowsky
For years, Johnson & Johnson has been battling lawsuits alleging it played a role in creating the nationwide opioid epidemic. On Tuesday, just days after a high-profile trial win, the company scored major relief in appeals in a separate case.
read more
By Anastassia Gliadkovskaya
A new ranking of the 10 most cost-efficient hospitals in the U.S. reveals that if all hospitals matched their performance, $8 billion could be saved in Medicare dollars.
read more
By Angus Liu
Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a death reported to the FDA Adverse Event Reporting System (FAERS) will likely trigger more doubts around its use.
read more
By Andrea Park
After years of speculation and false starts, General Electric is officially spinning off its healthcare business into an independent company.
read more
By Sharon Klahr Coey
As with many diseases, Black women disproportionally bear the brunt of HIV. In 2019, 80% of new diagnoses were in going to women of color. GSK’s ViiV Healthcare tackles that disparity and more in season three of its award-winning podcast, “Being Seen.”
read more
By Conor Hale
After being tapped by sports stadiums and professional athletes, Cue Health is now planning a nationwide, direct-to-consumer launch of its cartridge-based self-test this month, alongside a virtual health platform that will provide access to electronic prescription services and digital results that can help clear the user for travel.
read more
By Heather Landi
Home and senior care platform Honor pulled in $370 million in new financing, Devoted Health notched a $1.15 billion funding round, Hinge Health clinched $400 million and other funding news from October.
read more
By Rebecca Torrence
Oak Street Health's stock plunged 22% on Tuesday morning after the company posted deeper-than-expected third-quarter losses and revealed they face a potential investigation by the DOJ. The tech-enabled value-based primary care provider reported a loss of 49 cents per share in the third quarter of 2021 and also revealed in a filing that the DOJ has requested information related to whether the company had violated the False Claims Act.
read more
By Kyle LaHucik
Flagship helped lead the way in messenger RNA by incubating Moderna. Now, the biotech founder wants to revolutionize transfer RNAs with $50 million dedicated to Flagship's newest venture, Alltrna.
read more
By Nick Paul Taylor
Mirati Therapeutics is looking to a KRAS-Keytruda combination to give it an edge over Amgen in lung cancer. After lowering the dose of its KRAS drug, Mirati saw around 60% of first-line patients respond to the combination—and lessened the tolerability concerns that initially held back the cocktail.
read more
By Andrea Park
The San Francisco-based company’s new funding will be used to help fine-tune the platform, which uses mechanical methods to deliver engineered DNA into cell therapies.
read more
By Andrea Park
Arthrex agreed to a settlement with the U.S. Department of Justice over allegations that it paid an orthopedic surgeon to recommend and use its products, leading to improper requests for Medicare reimbursement.
read more
